We Have Vaccines, Now Comes The Hard Part

While the scientific community awaits detailed data from leadingvaccine developers, several questions remain.

Dec. 14, 2020, 7:42 p.m.

Recent good news on vaccines for COVID-19 brings us closer to ending the acute phase of this terrible pandemic. But the sense of collective relief must be accompanied by a healthy dose of reality.

While the scientific community awaits detailed data from leading vaccine developers, several questions remain. Notably, it is still unclear how long immunity would last and whether it will prevent severe disease or prevent people from passing on the virus if already infected. This means that mitigation measures¾mask-wearing, social distancing, avoiding large crowds, and practicing good hygiene¾will likely be necessary for the foreseeable future.

Experts are urging the public to remain steadfast with precautionary measures for another reason. Even if the vaccine proved effective and was put on the market today, getting it to everyone who needs it will not happen overnight.

Billions of doses must reach billions of people—in every country.With competition for limited resources already impacting pandemic response, high-income countries have been accused of securing disproportionate amounts of limited vaccine supply for their own population—so-called “vaccine nationalism”.

All countries, especially those with fewer resources,must have rapid and equitable access to COVID-19 vaccines. Not only is it a moral imperative, global economic recovery depends on it. This is the motivation behind the Asia Pacific Vaccine Access Facility, a $9 billion initiative launched recently by the Asian Development Bank to help its developing members procure and deliver safe and effective vaccines against COVID-19.

Another initiative, the COVAX Advance Market Commitment (AMC)¾co-led by Gavi, the Vaccine Alliance, the Coalition for Epidemic Preparedness Innovations, and WHO¾is gearing up to provide 92 eligible low- and middle-income countries with access to successful vaccine candidates. It aims to deliver 2 billion doses of vaccine by the end of 2021.

Key and vulnerable populations, including health workers and the elderly, are slated to receive vaccines first through COVAX, and the AMC will provide doses for up 20%of the population of participating countries.

But this doesn’t account for how and when the rest of the population in eligible countries will access vaccines, or how other countries (mostly middle-income countries not participating in COVAX) will access them.

Perhaps more significantly, rolling-out the vaccine worldwide requires coordinated action within and across several complex systems—from manufacturing and storage, to shipping and distribution—and will require unprecedented global collaboration, including robust private-public sector partnerships.

Furthermore, health systems must adapt existing delivery strategies and information systems designed for child immunization to effectively distribute a vaccine to adults. The supply chains and health system capacity required to produce and distribute COVID-19 vaccine will be staggering.

We can draw useful lessons from how some parts of Asia and the Pacific have used robust public health systems and innovative approaches to push back on COVID-19.

The Republic of Korea’s success with testing and digital contact tracing may enable it to quickly develop digital vaccine tracking systems, Viet Nam’s targeted measures to maintain public confidence and prevent widespread COVID-19 outbreaks may help to engender public trust in the safety of a vaccine.Thailand’s use of village health volunteers to support the tracing of active cases can be mobilized to support vaccination of rural populations.

The following actions can be taken now by countries to ensure they are prepared to prioritize, introduce, and deliver COVID-19 vaccines:

Adopt a whole-of-government approach to improve vaccine delivery planning. Every aspect of successful COVID-19 response in the region—from the development of test kits to the designation of treatment facilities—has involved partnerships across society. Delivery of vaccines is no exception. Countries should engage key stakeholders to plan scenarios, develop a national vaccine strategy, and organize operational aspects of vaccine introduction.

Agree on the vaccine priority line. Who should receive the first doses of the vaccine is a complex question. Countries should assess how to identify priority groups based on their country context and specific epidemiology. They should also model different scenarios for vaccinating the general population and set expectations accordingly.

Develop communication strategies to improve vaccine uptake.Widespread campaigns will be necessary to educate the public about the benefits of vaccination, especially given reported vaccine hesitancy in many communities. With vaccine coverage essential to achieving herd immunity, developing and implementing clear advocacy and communication strategies will be critical.

Strengthen vaccination infrastructure.Virtually every country in the world will have to strengthen and expand its existing vaccination infrastructure. For example, the Pfizer vaccine will require storage at temperatures as low as minus 80º Celsius (-112º Fahrenheit). Additionally, temperature-controlled logistics and point-of-care cold chain infrastructure are unreliable at many rural areas in low- and middle-income countries.Key issues include strengthening vaccine storage, distribution systems and facilities,safety monitoring systems,and ways to track every dose that has been administered.

Vaccines do not save lives; vaccinations save lives. But vaccination in select countries will not end the acute phase of the pandemic.

Only timely vaccination in all countries will do that. So all countries need to start preparing, now.

Patrick Osewe is Chief of the Asian Development Bank’s Health Sector Group

More on Opinion

The Latest

Latest Magazine

VOL. 14 No. 10, January 08, 2021 ( Paush 24, 2077) Publisher: Keshab Prasad Poudel Online Register Number: DOI 584/074-75

VOL. 14 No. 09, December 25, 2020 ( Paush 10, 2077) Publisher: Keshab Prasad Poudel Online Register Number: DOI 584/074-75

VOL. 14 No. 08, December 11, 2020 ( Mangsir 26, 2077) Publisher: Keshab Prasad Poudel Online Register Number: DOI 584/074-75

VOL. 14 No. 07, November 27, 2020 ( Mangsir 12, 2077) Publisher: Keshab Prasad Poudel Online Register Number: DOI 584/074-75